Home
AstraZeneca’s Imfinzi Product Has Been Approved in the EU as the First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

AstraZeneca’s Imfinzi Product Has Been Approved in the EU as the First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

Impacting News March 20, 2026

AstraZeneca'a Imfinzi

AstraZeneca (AZN) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, docetaxel) has been approved in the European Union (EU) for the treatment of adult patients with resectable . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Impacting News
March 20, 2026

Other Articles